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Patients with hepatic metastases of melanoma have a very
poor prognosis, with a median overall survival of less than
6 months. There are several small heterogeneous studies
that have shown an association with prolonged survival
in those patients treated with hepatic resection, but the role
of surgery remains unclear. We evaluated the safety and
efficacy of hepatic resection in a population-based study
in the Netherlands for patients with metastatic melanoma
and assessed the factors that could affect disease-free
and overall survival. Patients with hepatic melanoma
metastases who underwent potentially curative
resection were identified between 1994 until 2010 using
the PALGA database, a nation-wide network and registry
of histopathology and cytopathology in the Netherlands.
They were retrospectively evaluated for clinical and
pathological factors with respect to recurrence and
survival using Kaplan–Meier curves to assess survival
and univariate regression analysis for the assessment
of potential prognostic factors. A total of 32 patients
were identified in 15 hospitals, 19 men and 13 women.
The median age of the patients at the time of hepatic
resection was 52 years (range 27–69). Postoperative
complications occurred in five patients (15%), without
postoperative mortality. The median follow-up was
21 months (range 3–65). The median disease-free
survival was 11 months (range 0–57) and the median
overall survival was 29 months (range 4–66). Significant
prognostic factors for overall survival in univariate analysis
were the distribution and number of metastases, as well as
the type of hepatic resection (major or minor). Hepatic
resection in patients with resectable metastatic melanoma
is safe and might be associated with a prolonged survival
in a highly selected group of patients. Melanoma Res
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Introduction
Depending on the clinical and pathological characteristics
of the primary tumor, up to one third of patients with
melanoma develop distant metastases [1–3]. A common
site for distant metastases is the liver. Especially patients
with ocular melanoma may have hepatic metastases
present at the time of diagnosis, in 40% of the cases,
and the liver becomes involved in 95% of patients who
develop metastatic disease [4]. Cutaneous melanoma also
metastasizes to the liver in 15–20% of the patients who
develop metastatic disease and, on autopsy, hepatic
involvement is found in 55–75% of patients [3,5].
Patients with hepatic metastases have a very poor pro-
gnosis, with a median survival of approximately 4 months
and a 5-year survival of less than 5% [6]. Response rates
on traditional DTIC-based chemotherapy regimens are
often low, with percentages below 10% [7]. Recent treat-
ment with BRAF inhibitors or anti-CTLA4 has yielded
response rates with a significant improvement in the
1-year survival, but the long-term survival benefits are to
be awaited [8,9]. Moreover, these new agents may induce
complications, with considerable morbidity and develop-
ment of other skin cancers. The optimal treatment
strategy for patients with isolated hepatic melanoma
metastases remains unclear, even with these new
treatment options.
In patients with colorectal liver metastases, hepatic
resection has widely been proven effective, with a 5-year
survival of 20–50% [10–12]. With improvements in
surgical techniques and anesthetic management, the
perioperative mortality and morbidity have decreased,
which makes partial hepatic resections relatively safe.
However, patients with disseminated malignancies of
noncolorectal, non-neuroendocrine origin to the liver are
only referred for surgical therapy in selected cases.
The objective of this study was to evaluate all patients in
the Netherlands in the past 20 years with metastatic
melanoma of the liver who were treated with hepatic
resection for safety, survival, and to identify potential
prognostic factors to predict long-term survival after
resection.
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Patients and methods
Patients and data collection
Patients were identified by the results of a nation-wide
research question in the PALGA-database, a nation-wide
network and registry of histopathology and cytopathology
in the Netherlands, which registers all pathologic reports
since 1991 [13]. All patients who underwent a potentially
curative liver resection for metastatic melanoma between
1994 and 2010 were included. Hospitals were visited
to collect retrospective data from the patient files.
The following data were collected for each patient from
the file: demographics, anatomical location, and histo-
logical characteristics of the primary melanoma, details of
the primary treatment of the melanoma, time interval
from initial treatment of the melanoma to metastasis,
surgical procedures, number, location and size of the
hepatic metastases, recurrence, death date, mortality, and
morbidity.
Outcome variables
Postoperative mortality and morbidity included all deaths
or complications attributed to the hepatic resection and
all deaths or complications within 60 days of the operative
procedure. Disease-free survival was defined as the time
from hepatic resection until disease recurrence. In some
patients, resection had not been completed and disease-
free survival was defined as 0 months. Overall survival was
defined as the time between hepatic resection until the
date of the last follow-up or death. Death was not
specified by cause, as it was not possible to detect this
because of the ethical guidelines of using de-identified
data.
Statistical analysis
All statistical analyses were carried out using the
Statistical Package for the Social Sciences (SPSS Inc.,
Chicago, Illinois, USA; version 16.0). Survival outcomes
were calculated using Kaplan–Meier survival curves.
Prognostic factors for long-term survival were identified
by univariate analysis according to the Cox proportional
hazard regression methodology. Because of the small
number of patients, multivariate analysis was not carried
out. We considered a P-value of less than 0.05 as
significant.
Results
Patient and tumor characteristics
A total of 49 patients were identified in 15 hospitals using
the PALGA database; eight patients underwent only a
diagnostic liver biopsy, two patients underwent an
isolated liver perfusion, and seven patients were found
to have unresectable disease preoperatively. A total of
32 patients who underwent hepatic resection between
1994 and 2010 were evaluated in the present study.
The median follow-up was 21 months (range 3–65).
The median age during hepatic resection was 52 years
(range 27–69). There were 19 men and 13 women. The
median interval between resection of the primary tumor
and the hepatic resection was 62 months (range 15–188).
The origin of the primary tumor was ocular melanoma in
12 patients and cutaneous melanoma in 16 patients; in
four patients, the primary location of the tumor was
unknown. The median Breslow thickness of the primary
tumor was 2.0mm (range 0.5–11.0mm). Before hepatic
resection, 13 patients were treated with a therapeutic
lymph node dissection for regional metastatic disease
(inguinal lymph node dissection, n=5; axillary lymph
node dissection, n=10; and cervical lymph node dissec-
tion, n=1). In 16 patients, the hepatic metastases were
the first and only site of metastases.
Surgery characteristics
The number of metastases ranged from 1 to 10; 18 of
the patients (52%) had a solitary hepatic metastasis.
The distribution of the metastases was unilobar in 23
patients and bilobar in nine patients. The median size
of the largest metastasis was 24mm (range 10–160mm).
Patients were treated with a hemihepatectomy (n=9),
extended hemihepatectomy (n=2), segmentectomy
(n=11), or a nonanatomical resection (n=10). Resection
was radical (R0) in 23 patients, microscopically irradical
(R1) in six patients, macroscopically irradical (R2) in one
patient, and unknown in two patients.
Postoperative mortality was not observed. Postoperative
complications occurred in five patients (15%). Four
patients developed either liver failure, ileus, pneumonia,
or pleural effusion. All of these complications resolved
with conservative treatment. One patient developed
an intra-abdominal infected hematoma, which required
percutaneous drainage and antibiotic treatment. The
seven patients who underwent explorative laparotomy
and were found to have unresectable disease did not
experience postoperative morbidity.
Overall survival and disease-free survival
The median disease-free survival was 11 months (range
0–57 months) and the median overall survival was 29
months (range 4–64 months) (Fig. 1a and b). There was
one patient with a survival of more than 5 years, and the
5-year overall survival was 3%.
Prognostic factors
Significant factors for prolonged disease-free survival in
univariate analysis were the number of hepatic metas-
tases and a cutaneous location of the primary melanoma
(Table 1). Significant factors associated with prolonged
overall survival in univariate analysis were the number
(P=0.023) and the distribution of hepatic metastases
(P=0.002), as well as a minor resection (P=0.021)
(Fig. 2a–c). There was a trend toward prolonged survival
in male versus female patients (P=0.054).
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Discussion
This study describes the first nation-wide series of
melanoma patients in the Netherlands treated surgically
for hepatic metastases in the last 20 years. A histological
diagnosis was available in 49 patients and only 32 (65%)
patients underwent a potentially curative surgical resec-
tion. The median overall survival in this small and highly
selective group of patients was 29 months. In univariate
analysis, patients with solitary metastasis, unilobar dis-
ease, or a minor resection (less than three segments) had
a significantly improved overall survival. Although this
study had a small number of patients, it confirms results
from previous studies in the literature and provides
additional data.
In the literature, metastatic melanoma patients receiving
systemic treatment without surgical treatment have
a median survival of less than 6 months [6]. Several
surgical studies have shown an association between
hepatic resection in melanoma patients and improved
survival in patients with stage IV disease [14–38]. Adam
et al. [23] reported a large series of patients with meta-
static melanoma who underwent hepatic resection;
they found a median disease-free and overall survival
rate of 11 and 35 months, respectively. Pawlik et al. [25]
also reported a series of 40 patients who underwent
hepatic resection for metastatic melanoma. They found
a median disease-free and overall survival of 8 and
28 months, respectively. Multiple other studies have
reported similar overall survival rates (Table 2).
Data from the present study support the results found in
previous studies, although the 5-year-overall survival was
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(a) Disease-free survival of patients who underwent hepatic resection for metastatic melanoma in months. Median disease-free survival: 11 months.
(b) Overall survival of patients who underwent hepatic resection for metastatic melanoma in months. Median overall survival: 29 months.
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these percentages range between 36% [23] and 10% [25].
This may partly be explained by the short median follow-
up time of 21 months. The 3-year overall survival and
4-year overall survival rates are 22%, respectively, 12.5%,
which are more in agreement with data found in the
literature. Several investigators have attempted to iden-
tify criteria to make the decision for hepatic resection in
metastatic liver disease. For colorectal hepatic meta-
stases, Fong et al. [39] have made specific recommenda-
tions on the basis of the number and size of metastases,
disease-free interval from primary to metastases, pre-
sence of lymph node positivity, and preoperative carcino-
embryonic antigen levels. There are fewer reports on the
selection of patients for hepatic resection in noncolo-
rectal, non-neuroendocrine metastases and even less
reports specifically for metastatic melanoma.
In previous studies, a number of different prognostic
factors have been shown to be important for survi-
val [17,18,20,21,24,28–30,37]. These differences could
possibly be explained by the small number and the
diverse clinical characteristics, particularly the origin of
the primary tumor, in the patients reported. Pawlik and
colleagues reported a significantly improved long-term
survival in patients with primary cutaneous melanoma,
with 5-year survival rates in this group of 20.5% versus no
survivors in the patients with primary ocular melanoma.
Table 1 Potential prognostic factors in univariate analysis for
disease-free survival and overall survival after hepatic resection







Sex – – 0.153 – 0.054
Male 19 14 – 38 –
Female 13 8 – 25 –
Primary tumor – – 0.033 – 0.996
Cutaneous 16 15 – 25 –
Ocular 12 8 – 34 –
Unknown 4 9 – 29 –
Breslow’s depth (mm) – – 0.875 – 0.623
<2 8 8 – 22 –
>2 7 15 – 25 –
Number metastases – – 0.030 – 0.023
Solitary 18 14 – 38 –
Z2 13 8 – 25 –
Distribution – – 0.301 – 0.002
Unilobar 23 14 – 38 –
Bilobar 9 8 – 22 –
Resection – – 0.687 – 0.021
<3 segments 13 13 – 38 –
>3 segments 19 7 – 22 –
Resection margins – – 0.000 – 0.905
R0 23 15 – 25 –
R1/R2 7 0 – 29 –
Age at the time of hepatic
resection (years)
– – 0.715 – 0.623
<60 25 10 – 31 –
>60 7 4 – 25 –
Size metastasis (mm) – – 0.279 – 0.453
<50 27 8 – 29 –
>50 5 2 – 11 –






















































(a) Overall survival (OS) in months after hepatic resection for metastatic
melanoma in patients with a unilobar (n=23; median OS 38 months)
or a bilobar (n=9; median OS 22 months) distribution (P=0.002).
(b) Overall survival (OS) in months after hepatic resection for metastatic
melanoma in patients with solitary (n=18; median OS 38 months)
or multiple hepatic metastases (n=13; median OS 25 months)
(P=0.023). (c) Overall survival (OS) in months in patients after minor
hepatic resection, which includes less than three liver segments
(n=13, median OS 38 months), or major hepatic resection, which
includes three or more liver segments (n=19; median OS 22 months)
for metastatic melanoma (P=0.021).
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They did not find other clinicopathological factors to be
predictive for an improved long-term survival. Unlike
the results of Adam et al. [23], the size of the hepatic
metastases was not a prognostic factor for long-term
survival in the present study. This might be explained by
the fact that only five patients with a diameter of more
than 5 cm were identified and 27 had a diameter of less
than 5 cm. R0-resection was also not a significant
predictive factor for long-term survival. According to the
different levels of significance reported, the various
factors are no absolute reasons to include or exclude
patients for hepatic resection, but can be taken into
account in providing optimal treatment for individual
patients.
In the present study, there was no mortality, but five of
the 32 patients (15%) experienced postoperative com-
plications. This complication rate might be a reflection of
an independent registration of the results by an external
reviewer, but may also relate to the relatively low number
of patients treated in each center. Mortality did not occur
in this series, but centralization of liver surgery might
possibly decrease the number of complications in the fu-
ture. Initiatives to further centralize and register patients
in a nation-wide database are now being implemented
in several countries including the Netherlands.
Especially in melanoma patients, immunological treat-
ment modalities have been studied intensively, with
promising results [8,40,41]. Recent reports show an
improved survival in patients treated with ipilimumab
or activated, mutated BRAF inhibitors [42]. The role of
surgery in patients with stage IV who become resectable
after treatment with these new agents has to be
established. Besides systemic treatment, other modalities
such as isolated liver perfusion have been explored in
patients with melanoma metastases in the liver. Various
reports show survival benefit in patients treated with
melphalan or TNF, but these treatments are still experi-
mental and survival benefit is limited, with a median
survival of approximately 10 months [43–45]. The ideal
therapeutic approach for melanoma patients with limited
liver metastases is unclear; however, complete metasta-
sectomy must be considered as a treatment option in
highly selected patients [46].
Conclusion
Hepatic resection is safe in resectable metastatic
melanoma and might be associated with a prolonged
survival in highly selected patients.
Collaborators
T.J.M. Ruers (Department of Surgery, Netherlands
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of Surgery, OLVG, Amsterdam), R.J. Porte (Department
of Surgery, Leids University Medical Centre, Leiden),
A.M. Rijken (Department of Surgical Oncology, University
Medical Centre, Utrecht), M.P. van den Tol (Department
of Surgery, University Medical Centre, Groningen),
M.F. Gerhards (Department of Surgery, Amphia Hospital,
Breda), M. S. L. Liem (Department of Surgery, Deventer
Hospital, Deventer), M. H. Bemelmans (Department
of Surgery, University Medical Centre Maastricht,
Maastricht), B. Ramshorst (Department of Surgery,
Sint Antonius Hospital, Nieuwengein), C. L. H. van
Table 2 Review of reports describing the factors associated with improved survival in patients with metastatic melanoma who underwent
hepatic resection
References Year N OS DFS Prognostic factors
Adam et al. [23] 2006 148 35 11 Ager60 DFIZ12 months
No extrahepatic disease R0/1-resection
Minor hepatic resectionb





Frenkel et al. [24] 2009 35 15–55 35–37 R0-resection r6 metastasesa
Rose et al. [21] 2001 24 28 12 R0-resection
O’Rourke et al. [18] 2007 20 42 18 R0-resection DFIZ24 monthsb
Weitz et al. [20] 2005 17 42 17 Size r5cm
No extrahepatic nodal diseaseb
Reddy et al. [37] 2007 11 44 13 DFIZ 6 months
Adjuvant chemoradiotherapyb
Herman et al. [36] 2006 10 22 NR NR
Elias et al. [32] 1998 10 18 NR NR
Present study 32 29 11 Solitary metastasis
Unilobar distribution
Minor hepatic resectiona
DFI, disease-free interval between resection of the primary tumor and detection of hepatic metastases; DFS, disease-free survival in months; NR, not reported;
OS, overall survival in months.
aStatistically significant (P<0.05) in univariate analysis.
bStatistically significant (P<0.05) in multivariate analysis.
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